Welcome to our dedicated page for Cardiff Oncology news (Ticker: CRDF), a resource for investors and traders seeking the latest updates and insights on Cardiff Oncology stock.
Cardiff Oncology, Inc. develops clinical-stage cancer therapies centered on PLK1 inhibition and its lead oral inhibitor onvansertib. Company news commonly covers onvansertib in RAS-mutated metastatic colorectal cancer, including the CRDF-004 Phase 2 program evaluating combinations with standard-of-care regimens such as FOLFIRI/bevacizumab and FOLFOX/bevacizumab.
Updates also include preclinical and investigator-initiated work in other oncology settings, including metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, triple-negative breast cancer, HER2-low breast cancer models and chronic myelomonocytic leukemia. Corporate releases also address oncology conference presentations, key opinion leader events, executive appointments, investor conferences and Nasdaq inducement equity grants.
Cardiff Oncology (Nasdaq: CRDF) reported Q1 2026 results and clinical progress for onvansertib in first-line RAS-mutated metastatic colorectal cancer.
Highlights include a successful End-of-Phase 2 FDA meeting, Phase 3 dose/regimen selection, strong Phase 2 ORR and PFS data, new leadership hires, and cash runway into Q1 2027.
Cardiff Oncology (Nasdaq: CRDF) announced an inducement equity grant for its new Chief Operating Officer, Dr. Aggarwal. The Compensation Committee approved non-qualified stock options to purchase 400,000 shares outside the 2021 Omnibus Plan.
The option was granted effective April 27, 2026 at an exercise price of $1.72 per share (closing price on the grant date) and vests over four years: 25% after 12 months, then monthly over 36 months, subject to continued employment.
Cardiff Oncology (Nasdaq: CRDF) will host a key opinion leader webinar on April 30, 2026 at 11:00 a.m. ET to discuss investigator-initiated trial data showing single-agent activity of onvansertib in chronic myelomonocytic leukemia (CMML).
Registration and live webcast access are available via the company Events page; a replay will be posted after the discussion.
Cardiff Oncology (Nasdaq: CRDF) will present updated Phase 2 data for onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC) at ASCO 2026. The rapid oral presentation (Abstract #3510) is scheduled for June 2, 2026, 8:00-9:30 AM CDT.
The abstract will be publicly available May 21, 2026, and the presentation will be posted on the company’s Scientific Publications page after ASCO.
Cardiff Oncology (Nasdaq: CRDF) will present preclinical poster data at AACR 2026 showing its oral PLK1 inhibitor onvansertib potentiates trastuzumab deruxtecan (T-DXd) in HER2-low breast cancer models.
The combination produced tumor regression in nearly all mice, with complete responses up to 62%, synergistic cell‑kill in resistant lines, extended event‑free survival, and favorable tolerability. Poster available April 19, 2026; online after presentation.
Cardiff Oncology (Nasdaq: CRDF) appointed Mani Mohindru, PhD, as President and Chief Executive Officer and named Josh Muntner as Chief Financial Officer (effective April 6, 2026) and Ajay Aggarwal, MD, MBA, as Chief Operating Officer (effective April 27, 2026).
Leadership hires aim to advance onvansertib in first-line RAS-mutant metastatic colorectal cancer. The company granted Mr. Muntner a non‑qualified option for 486,650 shares at an exercise price of $1.58, vesting over four years under Nasdaq inducement rule 5635(c)(4).
Cardiff Oncology (Nasdaq: CRDF) will host a key opinion leader webinar on March 25, 2026 at 4:30 p.m. ET focused on first-line RAS-mutated metastatic colorectal cancer (mCRC).
The session features KOLs Scott Kopetz, M.D., Ph.D., Heinz-Josef Lenz, M.D., and interim CEO Mani Mohindru, PhD, discussing onvansertib clinical data and its potential role in mCRC management.
Cardiff Oncology (Nasdaq: CRDF) will present new preclinical data on its oral PLK1 inhibitor onvansertib at the AACR Annual Meeting 2026 in San Diego.
The poster (Abstract 329) shows onvansertib enhanced antitumor activity and reversed resistance to trastuzumab deruxtecan (T-DXd) in therapy-resistant HER2-low breast cancer models. Presentation: April 19, 2026, 2:00 PM–5:00 PM PT. The poster will be posted to the company’s Scientific Publications page after the session.
Cardiff Oncology (Nasdaq: CRDF) announced that management will participate in three investor conferences in March 2026: TD Cowen on 03/04/26, Barclays on 03/10/26 and Leerink Partners on 03/11/26. Interested parties can view live webcasts and replays via the company’s Events page.
Cardiff Oncology (Nasdaq: CRDF) reported positive Phase 2 CRDF-004 results in first-line RAS-mutated metastatic colorectal cancer and provided full-year 2025 financials and a business update.
The 30 mg onvansertib + FOLFIRI/bev arm achieved a confirmed ORR of 72.2% versus 43.2% for combined SoC, and showed improved PFS (HR: 0.37, p<0.05). The company held $58.3M cash, expecting runway into Q1 2027, and named an interim CEO while searching for permanent CEO and CFO.